To estimate biologic influence on heart failure (HF) risk in rheumatoid arthritis. Retrospective cohort (RECORD Study of Italian Society for Rheumatology) study on administrative healthcare databases. We identified 2527 patients treated with either etanercept (n = 1690) or abatacept (n = 837). HF incidence rate was higher in the abatacept cohort than in the etanercept cohort with a 2.38 (95% CI 1.08–5.27) crude competing risk HR (SHR) for abatacept of developing HF, not confirmed after adjustment for prespecified confounders (SHR 1.43; 95% CI 0.51–3.98). Abatacept, compared to etanercept, is prescribed to patients with a worse cardiovascular profile but does not increase the risk of developing HF, when confounding factors are accounted for.

Generali, E., Carrara, G., Kallikourdis, M., Condorelli, G., Bortoluzzi, A., Scire, C., et al. (2019). Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. RHEUMATOLOGY INTERNATIONAL, 39(2), 239-243 [10.1007/s00296-018-4196-9].

Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept

Condorelli G.;Scire C. A.
Penultimo
;
2019

Abstract

To estimate biologic influence on heart failure (HF) risk in rheumatoid arthritis. Retrospective cohort (RECORD Study of Italian Society for Rheumatology) study on administrative healthcare databases. We identified 2527 patients treated with either etanercept (n = 1690) or abatacept (n = 837). HF incidence rate was higher in the abatacept cohort than in the etanercept cohort with a 2.38 (95% CI 1.08–5.27) crude competing risk HR (SHR) for abatacept of developing HF, not confirmed after adjustment for prespecified confounders (SHR 1.43; 95% CI 0.51–3.98). Abatacept, compared to etanercept, is prescribed to patients with a worse cardiovascular profile but does not increase the risk of developing HF, when confounding factors are accounted for.
Articolo in rivista - Articolo scientifico
Biologic; Cardiovascular; DMARDs; Epidemiology;
English
2019
39
2
239
243
reserved
Generali, E., Carrara, G., Kallikourdis, M., Condorelli, G., Bortoluzzi, A., Scire, C., et al. (2019). Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. RHEUMATOLOGY INTERNATIONAL, 39(2), 239-243 [10.1007/s00296-018-4196-9].
File in questo prodotto:
File Dimensione Formato  
Generali et al. - 2019 - Risk of hospitalization for heart failure in rheum.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 736.17 kB
Formato Adobe PDF
736.17 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/355179
Citazioni
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 19
Social impact